Physician prescribing of anorexigenics for weight loss in Salt Lake County, Utah

Pharmacotherapy

Volumn 20, Issue 8I, 2000, Pages 967-973

  Gay, Christopher ^a   Shane McWhorter, Laura ^a,b   Williams, Kathy ^c,d   Stone, Mary Bishop ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c Family Practice Residency of Idaho ^*  (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE; SEROTONIN AGONIST;

ADULT; AGED; ARTICLE; COMORBIDITY; DRUG WITHDRAWAL; FEMALE; FOOD AND DRUG ADMINISTRATION; GENERAL PRACTICE; HUMAN; MALE; OBESITY; PRESCRIPTION; PRIMARY MEDICAL CARE; SEROTONIN SYNDROME; UNITED STATES; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

EID: 0033843098     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.11.967.35267     Document Type: Article

References (21)

1. Position of the American Dietetic Association - Weight management
2. Medical hazards of obesity
3. The disease burden associated with overweight and obesity
4. Annual deaths attributable to obesity in the United States
5. Actual causes of death in the United States
6. The cost of obesity: The US perspective
7. Long-term pharmacotherapy in the management of obesity
8. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report
9. Use and abuse of appetite-suppressant drugs in the treatment of obesity
10. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine. U.S. Department of Health and Human Services interim public health recommendations, November 1997
11. Long-term weight control: The National Heart, Lung, and Blood Institute funded multimodal intervention study
12. Valvular heart disease associated with fenfluramine-phentermine
13. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs
14. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo
15. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation
16. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
17. Dexfenfluramine and serotonin neurotoxicity: Further clinical evidence that clinical caution is indicated
18. Pharmacologic induction of weight loss to treat type 2 diabetes